Etzer Darout
Stock Analyst at BMO Capital
(3.58)
# 729
Out of 4,479 analysts
73
Total ratings
41.67%
Success rate
8.51%
Average return
Main Sectors:
Top Industries:
24 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Maintains: Outperform | $34 → $32 | $19.02 | +68.24% | 3 | Jun 14, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $29 → $31 | $8.13 | +281.30% | 1 | Jun 13, 2024 | |
| MRUS Merus | Maintains: Outperform | $84 → $91 | $54.45 | +67.13% | 5 | Jun 4, 2024 | |
| ACRV Acrivon Therapeutics | Reiterates: Outperform | $25 | $5.86 | +326.62% | 5 | May 15, 2024 | |
| FATE Fate Therapeutics | Maintains: Market Perform | $7 → $6 | $3.26 | +84.05% | 7 | May 10, 2024 | |
| MGNX MacroGenics | Downgrades: Market Perform | $24 → $8 | $4.30 | +86.05% | 7 | May 10, 2024 | |
| CTMX CytomX Therapeutics | Maintains: Market Perform | $3.25 → $3.59 | $1.33 | +169.92% | 9 | May 9, 2024 | |
| BNTX BioNTech SE | Maintains: Outperform | $123 → $122 | $78.83 | +54.76% | 3 | May 7, 2024 | |
| AZN AstraZeneca | Maintains: Outperform | $80 → $82 | $77.94 | +5.21% | 4 | Apr 26, 2024 | |
| NVS Novartis AG | Maintains: Market Perform | $114 → $116 | $106.54 | +8.88% | 2 | Apr 24, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $18 → $19 | $6.85 | +177.37% | 2 | Mar 15, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $16 → $26 | $11.83 | +119.78% | 5 | Mar 4, 2024 | |
| NUVL Nuvalent | Maintains: Outperform | $93 → $102 | $75.51 | +35.08% | 4 | Feb 28, 2024 | |
| ARVN Arvinas | Maintains: Outperform | $89 → $90 | $25.98 | +246.42% | 1 | Feb 28, 2024 | |
| GMAB Genmab | Upgrades: Outperform | $46 → $48 | $24.85 | +93.16% | 2 | Feb 23, 2024 | |
| CCCC C4 Therapeutics | Maintains: Outperform | $18 → $16 | $4.85 | +229.90% | 2 | Nov 3, 2023 | |
| IVA Inventiva | Reiterates: Buy | $12 | $2.92 | +311.66% | 2 | Sep 1, 2023 | |
| FHTX Foghorn Therapeutics | Maintains: Outperform | $20 → $19 | $5.84 | +225.34% | 2 | Apr 25, 2023 | |
| EXEL Exelixis | Initiates: Outperform | $28 | $22.25 | +25.84% | 1 | Jun 24, 2022 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Buy | $170 | $243.32 | -30.13% | 2 | Feb 3, 2022 | |
| VERV Verve Therapeutics | Initiates: Buy | n/a | $4.98 | - | 1 | Jul 12, 2021 | |
| AKRO Akero Therapeutics | Initiates: Buy | n/a | $23.16 | - | 1 | Feb 26, 2021 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | n/a | $34.16 | - | 1 | Sep 9, 2020 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | n/a | $1.15 | - | 1 | Mar 28, 2018 |
Xencor
Jun 14, 2024
Maintains: Outperform
Price Target: $34 → $32
Current: $19.02
Upside: +68.24%
Scholar Rock Holding
Jun 13, 2024
Maintains: Outperform
Price Target: $29 → $31
Current: $8.13
Upside: +281.30%
Merus
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $54.45
Upside: +67.13%
Acrivon Therapeutics
May 15, 2024
Reiterates: Outperform
Price Target: $25
Current: $5.86
Upside: +326.62%
Fate Therapeutics
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $3.26
Upside: +84.05%
MacroGenics
May 10, 2024
Downgrades: Market Perform
Price Target: $24 → $8
Current: $4.30
Upside: +86.05%
CytomX Therapeutics
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $1.33
Upside: +169.92%
BioNTech SE
May 7, 2024
Maintains: Outperform
Price Target: $123 → $122
Current: $78.83
Upside: +54.76%
AstraZeneca
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $77.94
Upside: +5.21%
Novartis AG
Apr 24, 2024
Maintains: Market Perform
Price Target: $114 → $116
Current: $106.54
Upside: +8.88%
Terns Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $18 → $19
Current: $6.85
Upside: +177.37%
Y-mAbs Therapeutics
Mar 4, 2024
Maintains: Outperform
Price Target: $16 → $26
Current: $11.83
Upside: +119.78%
Nuvalent
Feb 28, 2024
Maintains: Outperform
Price Target: $93 → $102
Current: $75.51
Upside: +35.08%
Arvinas
Feb 28, 2024
Maintains: Outperform
Price Target: $89 → $90
Current: $25.98
Upside: +246.42%
Genmab
Feb 23, 2024
Upgrades: Outperform
Price Target: $46 → $48
Current: $24.85
Upside: +93.16%
C4 Therapeutics
Nov 3, 2023
Maintains: Outperform
Price Target: $18 → $16
Current: $4.85
Upside: +229.90%
Inventiva
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $2.92
Upside: +311.66%
Foghorn Therapeutics
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.84
Upside: +225.34%
Exelixis
Jun 24, 2022
Initiates: Outperform
Price Target: $28
Current: $22.25
Upside: +25.84%
Alnylam Pharmaceuticals
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $243.32
Upside: -30.13%
Verve Therapeutics
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $4.98
Upside: -
Akero Therapeutics
Feb 26, 2021
Initiates: Buy
Price Target: n/a
Current: $23.16
Upside: -
Mirum Pharmaceuticals
Sep 9, 2020
Maintains: Buy
Price Target: n/a
Current: $34.16
Upside: -
Aclaris Therapeutics
Mar 28, 2018
Maintains: Outperform
Price Target: n/a
Current: $1.15
Upside: -